Suppr超能文献

载紫杉醇的立体稳定脂质体的抗血管生成活性:体外与体内研究。

Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.

机构信息

Department of Pharmaceutics, School of Pharmaceutical Sciences, Peking University, Xueyuan Road 38, Beijing, 100191, China.

出版信息

AAPS PharmSciTech. 2010 Jun;11(2):752-9. doi: 10.1208/s12249-010-9430-z. Epub 2010 May 5.

Abstract

The purpose of this present study was to evaluate the antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX). The SSL-PTX was prepared by the thin-film method. The release of paclitaxel from SSL-PTX was analyzed using a dialysis method. The effect of SSL-PTX on endothelial cell proliferation and migration was investigated in vitro. The antitumor and antiangiogenic activity of SSL-PTX was evaluated in MDA-MB-231 tumor xenograft growth in BALB/c nude mice. The release of paclitaxel from SSL-PTX was 22% within 24 h. Our in vitro results indicated that SSL-PTX could effectively inhibit the endothelial cell proliferation and migration at a concentration-dependent manner. We also observed that metronomic SSL-PTX induced marked tumor growth inhibition in MDA-MB-231 xenograft model via the antiangiogenic mechanism, unlike that in paclitaxel injection (Taxol) formulated in Cremophor EL (CrEL). Overall, our results suggested that metronomic chemotherapy with low-dose, CrEL-free SSL-PTX should be feasible and effective.

摘要

本研究旨在评估载紫杉醇的立体稳定脂质体(SSL-PTX)的抗血管生成活性。SSL-PTX 采用薄膜法制备,采用透析法分析紫杉醇的释放。体外研究 SSL-PTX 对内皮细胞增殖和迁移的影响。在 BALB/c 裸鼠 MDA-MB-231 肿瘤异种移植生长中评价 SSL-PTX 的抗肿瘤和抗血管生成活性。24 小时内,SSL-PTX 中紫杉醇的释放率为 22%。我们的体外结果表明,SSL-PTX 可浓度依赖性地有效抑制内皮细胞的增殖和迁移。我们还观察到,与紫杉醇注射液(Taxol)在 Cremophor EL(CrEL)中的制剂不同,低剂量、无 CrEL 的 SSL-PTX 经时化疗通过抗血管生成机制可显著抑制 MDA-MB-231 异种移植模型中的肿瘤生长。总的来说,我们的结果表明,低剂量、无 CrEL 的 SSL-PTX 的节拍化疗应该是可行且有效的。

相似文献

1
Antiangiogenic activity of sterically stabilized liposomes containing paclitaxel (SSL-PTX): in vitro and in vivo.
AAPS PharmSciTech. 2010 Jun;11(2):752-9. doi: 10.1208/s12249-010-9430-z. Epub 2010 May 5.
2
Anti-tumor and anti-angiogenic effect of metronomic cyclic NGR-modified liposomes containing paclitaxel.
Biomaterials. 2013 Jan;34(4):1102-14. doi: 10.1016/j.biomaterials.2012.10.029. Epub 2012 Nov 3.
4
Antitumor effect of iRGD-modified liposomes containing conjugated linoleic acid-paclitaxel (CLA-PTX) on B16-F10 melanoma.
Int J Nanomedicine. 2014 Jun 24;9:3091-105. doi: 10.2147/IJN.S65664. eCollection 2014.
6
Paclitaxel-Loaded Folate-Coated pH-Sensitive Liposomes Enhance Cellular Uptake and Antitumor Activity.
Mol Pharm. 2019 Aug 5;16(8):3477-3488. doi: 10.1021/acs.molpharmaceut.9b00329. Epub 2019 Jul 1.
7
Co-delivery of epirubicin and paclitaxel using an estrone-targeted PEGylated liposomal nanoparticle for breast cancer.
Int J Pharm. 2020 Jan 5;573:118806. doi: 10.1016/j.ijpharm.2019.118806. Epub 2019 Oct 31.
9
Liposomes encapsulating native and cyclodextrin enclosed paclitaxel: Enhanced loading efficiency and its pharmacokinetic evaluation.
Int J Pharm. 2018 Jan 30;536(1):95-107. doi: 10.1016/j.ijpharm.2017.11.048. Epub 2017 Nov 22.
10
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
J Control Release. 2015 Dec 28;220(Pt A):189-200. doi: 10.1016/j.jconrel.2015.10.018. Epub 2015 Oct 22.

引用本文的文献

4
Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect.
Nat Rev Clin Oncol. 2016 Nov;13(11):659-673. doi: 10.1038/nrclinonc.2016.64. Epub 2016 May 17.
5
Improved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma model.
PLoS One. 2014 Jul 29;9(7):e103736. doi: 10.1371/journal.pone.0103736. eCollection 2014.
6
Antitumor activity of dichloroacetate on C6 glioma cell: in vitro and in vivo evaluation.
Onco Targets Ther. 2013;6:189-98. doi: 10.2147/OTT.S40992. Epub 2013 Mar 14.
7
The pharmacological bases of the antiangiogenic activity of paclitaxel.
Angiogenesis. 2013 Jul;16(3):481-92. doi: 10.1007/s10456-013-9334-0. Epub 2013 Feb 7.
8
Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.
Int J Nanomedicine. 2012;7:4499-510. doi: 10.2147/IJN.S32817. Epub 2012 Aug 14.

本文引用的文献

2
Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer.
Int J Nanomedicine. 2009;4:99-105. doi: 10.2147/ijn.s3061. Epub 2009 Apr 20.
3
Active targeting schemes for nanoparticle systems in cancer therapeutics.
Adv Drug Deliv Rev. 2008 Dec 14;60(15):1615-26. doi: 10.1016/j.addr.2008.08.005. Epub 2008 Sep 20.
7
8
Nanoparticles for drug delivery in cancer treatment.
Urol Oncol. 2008 Jan-Feb;26(1):57-64. doi: 10.1016/j.urolonc.2007.03.015.
10
Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells.
Pharm Res. 2007 Dec;24(12):2402-11. doi: 10.1007/s11095-007-9425-y. Epub 2007 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验